Scholarlink

<p>Fungal infections represent a growing global health crisis, with antifungal drug resistance emerging as a critical challenge. Developing structurally novel compounds offers a promising strategy to address resistance mechanisms. In this work, we report the design, synthesis, and biological evaluation of lactose-benzothiazole thiourea conjugates formulated as nanoparticles for enhanced antifungal delivery. The synthesized compounds exhibited promising antifungal activity against <i>C. albicans</i>, with compound <b>3k</b> showing the most potent activity (MIC = 0.125&#xa0;μg/mL), comparable to fluconazole. Selected compounds also demonstrated antibacterial activity against <i>Staphylococcus epidermidis</i>. Molecular docking studies revealed favorable binding interactions with <i>C. albicans</i> lanosterol 14α-demethylase (CYP51, PDB: 1EA1), with binding energies of − 6.8 to − 7.7&#xa0;kcal/mol. To the best of our knowledge, this study presents the first report of lactose-benzothiazole thiourea conjugates as nanoparticle-based antifungal agents, demonstrating their potential to overcome drug resistance through alternative binding modes and enhanced cellular uptake, offering a promising scaffold for next-generation antifungal therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanoparticle antifungal agents: design, synthesis and docking studies of lactose thiourea derivatives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Shankesh C. Zyate,
  • Nikita V. Awajare,
  • Sanjay S. Gaikwad,
  • Kunal Raut,
  • Vikas Jha,
  • Amardeep R. Jadhao,
  • Poonam T. Agrawal

摘要

Fungal infections represent a growing global health crisis, with antifungal drug resistance emerging as a critical challenge. Developing structurally novel compounds offers a promising strategy to address resistance mechanisms. In this work, we report the design, synthesis, and biological evaluation of lactose-benzothiazole thiourea conjugates formulated as nanoparticles for enhanced antifungal delivery. The synthesized compounds exhibited promising antifungal activity against C. albicans, with compound 3k showing the most potent activity (MIC = 0.125 μg/mL), comparable to fluconazole. Selected compounds also demonstrated antibacterial activity against Staphylococcus epidermidis. Molecular docking studies revealed favorable binding interactions with C. albicans lanosterol 14α-demethylase (CYP51, PDB: 1EA1), with binding energies of − 6.8 to − 7.7 kcal/mol. To the best of our knowledge, this study presents the first report of lactose-benzothiazole thiourea conjugates as nanoparticle-based antifungal agents, demonstrating their potential to overcome drug resistance through alternative binding modes and enhanced cellular uptake, offering a promising scaffold for next-generation antifungal therapeutics.